Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.54 |
| ▸ | FYN | P06241 | 4/20 | 0.48 |
| ▸ | F2RL3 | Q96RI0 | 11/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943235 | 0.90 | MKNK1 (0.67) | MKNK1FYNF2RL3NPC1RAB9A | |
| SCHEMBL2950873 | 0.84 | MKNK1 (0.64) | MKNK1FYNF2RL3 | |
| SCHEMBL2940432 | 0.80 | MKNK1 (0.82) | MKNK1FYN | |
| SCHEMBL4691380 | 0.78 | MKNK1 (0.64) | MKNK1FYNF2RL3 | |
| SCHEMBL2947501 | 0.77 | MKNK1 (0.51) | MKNK1FYNF2RL3KDM4E | |
| SCHEMBL2940430 | 0.76 | MKNK1 (0.45) | MKNK1FYNF2RL3KDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL3453046 | 0.71 | FYN (0.41) | MKNK1FYNKDM4ENPC1HPGD | |
| SCHEMBL13110948 | 0.70 | FYN (0.54) | MKNK1FYNKDM4ENPC1HPGD | |
| SCHEMBL2943231 | 0.70 | MKNK1 (1.00) | MKNK1FYN | |
| Hydrochloric Acid SCHEMBL3452544 | 0.69 | FYN (0.53) | MKNK1FYNKDM4ENPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750000-B2 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093490-A1 | Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments | MAP4K2, MAP3K1, MAP3K2 | MKNK1 144/4885FYN 421/4885F2RL3 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.